Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Drug Safety|May 24, 2015
Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry AnalysisYoshinori Takeuchi, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
Pharmacoepidemiology and Drug Safety|July 25, 2019
Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort studyMaki Komamine, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
Clinical Pharmacology and Therapeutics|November 22, 2025
Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan's National Claims DatabaseHotaka Maruyama, Eiko Iwasa, Shinya Watanabe, et al.
Plos One|January 26, 2024
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in JapanHaruka Shida, Maki Komamine, Kazuhiro Kajiyama, et al.
Clinical Pharmacology and Therapeutics|April 18, 2021
Nested Case-Control Study Utilizing MID-NET® on Thrombocytopenia Associated With Pegfilgrastim in Patients Treated With Antineoplastic AgentsKazuhiro Kajiyama, Chieko Ishiguro, Takashi Ando, et al.
Therapeutic Innovation & Regulatory Science|December 27, 2025
Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®Hotaka Maruyama, Yuki Kinoshita, Takashi Ando, et al.
Clinical and Translational Science|November 1, 2022
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of JapanSono Sawada, Kazuhiro Kajiyama, Haruka Shida, et al.
Clinical Pharmacology and Therapeutics|January 17, 2023
Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real-World Data from the MID-NET in JapanYuki Kinoshita, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
The Journal of Dermatological Treatment|July 4, 2024
Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET<sup>®</sup> in JapanYusuke Okada, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
Clinical and Translational Science|April 2, 2025
New Function for Safety Signal Monitoring in MID-NET<sup>®</sup>: The Case of an Anti-COVID-19 DrugYusuke Okada, Takashi Ando, Fumitaka Takahashi, et al.
Pageof 2